Table 5. . Summary findings of sensitivity analyses rt-CGM versus SMBG.
| Analysis | Total costs, CAD | Quality-adjusted life expectancy, QALYs | ICUR, CAD per QALY gained | ||||
|---|---|---|---|---|---|---|---|
| rt-CGM | SMBG | Difference | rt-CGM | SMBG | Difference | ||
| Base case | 207,466 | 189,863 | 17,603 | 9.97 | 9.02 | 0.95 | 18,523 |
| No QoL benefit with rt-CGM | 207,466 | 189,683 | 17,603 | 9.54 | 9.02 | 0.52 | 33,761 |
| QoL benefit with rt-CGM -50% | 207,466 | 189,683 | 17,603 | 9.76 | 9.02 | 0.74 | 23,923 |
| QoL benefit with rt-CGM +50% | 207,466 | 189,683 | 17,603 | 10.19 | 9.02 | 1.17 | 15,112 |
| Added QoL benefit for reduced FoH with rt-CGM | 207,466 | 189,683 | 17,603 | 10.33 | 9.02 | 1.31 | 13,407 |
| A1C treatment effect -50% | 214,904 | 189,863 | 25,041 | 9.84 | 9.02 | 0.82 | 30,631 |
| A1C treatment effect +50% | 199,612 | 189,863 | 9749 | 10.11 | 9.02 | 1.09 | 8978 |
| Number of SMBG per day = 1 | 207,446 | 178,573 | 28,893 | 9.97 | 9.02 | 0.95 | 30,404 |
| Number of SMBG per day = 2 | 207,466 | 182,605 | 24,861 | 9.97 | 9.02 | 0.95 | 26,161 |
| Number of SMBG per day = 4 | 207,466 | 190,670 | 16,796 | 9.97 | 9.02 | 0.95 | 17,675 |
| Number of SMBG per day = 5 | 207,466 | 194,702 | 12,764 | 9.97 | 9.02 | 0.95 | 13,432 |
| Number of SMBG per day = 10 | 207,466 | 214,863 | -7397 | 9.97 | 9.02 | 0.95 | Dominant |
| Time horizon = 10 years | 82,086 | 68,150 | 13,936 | 5.73 | 5.29 | 0.44 | 31,666 |
| Time horizon = 15 years | 120,519 | 104,206 | 16,313 | 7.51 | 6.88 | 0.63 | 26,101 |
| Time horizon = 20 years | 154,492 | 138,214 | 16,278 | 8.71 | 7.95 | 0.76 | 21,413 |
| Baseline mean age 30 years | 857,949 | 876,976 | -19,027 | 19.48 | 17.76 | 1.72 | Dominant |
| Baseline mean age 40 years | 635,293 | 639,649 | -4356 | 17.02 | 15.44 | 1.58 | Dominant |
| Baseline mean age 50 years | 402,555 | 392,433 | 10,122 | 13.95 | 12.63 | 1.32 | 7651 |
| Discount rate = 0% | 257,059 | 237,559 | 19,500 | 11.71 | 10.56 | 1.16 | 16,853 |
| Discount rate = 3% | 170,486 | 154,476 | 16,010 | 8.61 | 7.81 | 0.79 | 20,172 |
| Complication costs -20% | 176,234 | 154,955 | 21,279 | 9.97 | 9.02 | 0.95 | 22,392 |
| Complication costs +20% | 238,698 | 224,771 | 13,927 | 9.97 | 9.02 | 0.95 | 14,655 |
| Annual cost of rt-CGM -50% | 181,813 | 189,863 | -8050 | 9.97 | 9.02 | 0.95 | Dominant |
| Annual cost of rt-CGM -25% | 194,640 | 189,863 | 4777 | 9.97 | 9.02 | 0.95 | 5026 |
| Annual cost of rt-CGM +25% | 220,292 | 189,863 | 30,429 | 9.97 | 9.02 | 0.95 | 32,021 |
| SHE rate in rt-CGM arm 2 per 100 person-years | 207,791 | 189,863 | 17,928 | 9.95 | 9.02 | 0.93 | 19,269 |
| SHE rate in rt-CGM arm 4 per 100 person-years | 208,455 | 189,863 | 18,592 | 9.935 | 9.02 | 0.91 | 20,344 |
| Ketoacidosis disutility -0.0367 | 207,466 | 189,863 | 17,603 | 9.971 | 9.02 | 0.95 | 18,510 |
A1C: Glycated hemoglobin; FoH: Fear of hypoglycemia; ICUR: Incremental cost-utility ratio; QALY: Quality-adjusted life year; QoL: Quality of life; rt-CGM: Real-time continuous glucose monitoring; SMBG: Self-monitoring of blood glucose.